Differences in the survival of patients with recurrent versus de novo metastatic KRAS‐mutant and EGFR‐mutant lung adenocarcinomas
Open Access
Abstract
BACKGROUND Prognostic variables are independently associated with survival and are fundamental to clinical trial design. In the current study, the authors evaluated the impact of stage of disease at the time of the initial diagnosis on overall survival (OS) in 2 independent, oncogene‐defined cohorts. METHODS All patients with epidermal growth factor receptor (EGFR)‐mutant and KRAS‐mutant metastatic lung adenocarcinomas were identified through routine molecular testing from January 2005 through January 2011. Clinical characteristics were obtained. OS from the date of diagnosis of recurrent or de novo metastatic disease was estimated using the Kaplan‐Meier method. RESULTS A total of 635 patients with KRAS‐mutant and 496 patients with EGFR‐mutant metastatic lung adenocarcinomas were identified. Among patients with KRAS‐mutant lung adenocarcinomas, those with de novo metastatic disease were found to have a shorter median OS compared with those with recurrent metastatic disease (13 months vs 18 months; P = .003). In a multivariable analysis of patients with KRAS‐mutant lung adenocarcinomas, de novo metastatic disease at the time of diagnosis (TNM stage IV vs stage I‐III: hazard ratio, 1.5 [95% confidence interval, 1.2‐1.8]; P<.001) was independently associated with shorter OS. In patients with EGFR‐mutant lung adenocarcinomas, after controlling for age and Karnofsky performance status, de novo metastatic disease at the time of diagnosis (stage IV vs stage I‐III: hazard ratio, 1.3 [95% confidence interval, 1.0‐1.7]; P = .03) was found to be independently associated with shorter OS. CONCLUSIONS Among patients with KRAS‐mutant lung adenocarcinomas, stage of disease at diagnosis was associated with OS from the time of diagnosis of recurrent/metastatic disease. In multivariable analyses, in both patients with EGFR‐mutant and KRAS‐mutant lung adenocarcinomas, advanced stage at the time of diagnosis was found to be independently associated with shorter survival. Stage at diagnosis is a prognostic variable that should be accounted for in prospective studies in patients with metastatic lung adenocarcinomas. Cancer 2015;121:2078–2082. © 2015 American Cancer Society.Keywords
This publication has 16 references indexed in Scilit:
- Phase III Study of Afatinib or Cisplatin Plus Pemetrexed in Patients With Metastatic Lung Adenocarcinoma With EGFR MutationsJournal of Clinical Oncology, 2013
- Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): a multicentre, open-label, randomised phase 3 trialThe Lancet Oncology, 2012
- Detection of EGFR mutations in plasma DNA from lung cancer patients by mass spectrometry genotyping is predictive of tumor EGFR status and response to EGFR inhibitorsLung Cancer, 2011
- Survival differences among women with de novo stage IV and relapsed breast cancerAnnals of Oncology, 2010
- The IASLC Lung Cancer Staging Project: Validation of the Proposals for Revision of the T, N, and M Descriptors and Consequent Stage Groupings in the Forthcoming (Seventh) Edition of the TNM Classification of Malignant TumoursJournal of Thoracic Oncology, 2007
- Survival After Recurrent Nonsmall-Cell Lung Cancer After Complete Pulmonary ResectionThe Annals of Thoracic Surgery, 2007
- Rapid Polymerase Chain Reaction-Based Detection of Epidermal Growth Factor Receptor Gene Mutations in Lung AdenocarcinomasThe Journal of Molecular Diagnostics, 2005
- KRAS Mutations and Primary Resistance of Lung Adenocarcinomas to Gefitinib or ErlotinibPLOS Medicine, 2005
- EGF receptor gene mutations are common in lung cancers from “never smokers” and are associated with sensitivity of tumors to gefitinib and erlotinibProceedings of the National Academy of Sciences of the United States of America, 2004
- Karnofsky and ECOG performance status scoring in lung cancer: A prospective, longitudinal study of 536 patients from a single institutionEuropean Journal of Cancer, 1996